(NASDAQ: OABI) Omniab's forecast annual revenue growth rate of 14.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.39%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.3%.
Omniab's revenue in 2026 is $40,211,000.On average, 9 Wall Street analysts forecast OABI's revenue for 2026 to be $5,490,911,671, with the lowest OABI revenue forecast at $5,079,585,574, and the highest OABI revenue forecast at $5,880,212,860. On average, 8 Wall Street analysts forecast OABI's revenue for 2027 to be $6,762,376,063, with the lowest OABI revenue forecast at $5,210,568,140, and the highest OABI revenue forecast at $11,027,040,041.
In 2028, OABI is forecast to generate $9,111,602,345 in revenue, with the lowest revenue forecast at $5,574,781,354 and the highest revenue forecast at $15,774,793,392.